ARVN
ARVINAS, INC.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 23 to Feb 27 ▼ 2 days of insider sells: $581.7K by 4 insiders, avg $12.98
- Mar 6 ▲ 1 insider buy $268.1K at $13.40
- Mar 18 ▼ 1 insider sell $71.4K at $11.10
- May 1 ▲ Arvinas announced FDA approval of VEPPANU (vepdegestrant) for ER+/HE…
- May 1 ▲ Arvinas (ARVN) announced FDA approval of VEPPANU (vepdegestrant), th…
- May 11 ▼ 5 insiders sell $432.1K at $9.94
- May 12 ▼ Arvinas reported Q1 2026 revenue of $15.6M (down 91.7% YoY from $188…
- May 21 ▼ 1 insider sell $20.0K at $9.04
- Jun 17 to Jun 24 ▼ 2 days of insider sells: $66.0K by 2 insiders, avg $7.98
- Aug 5 ▼ Wells Fargo downgrades
- Nov 3 ▲ Earnings: ARVN Q3 2026 Earnings: EPS $-0.82 (+7.7% vs est)
- Nov 9 ▼ 1 insider sell $1.5K at $6.36
Signal stack
Where each data set points today.
- InsidersBEARISH
1 insider bought $268.1K at an average $13.40. 6 insiders sold $1.2M. Price is 49% below their cost.
- InstitutionsBULLISH
Q3 2026: 21 added (0 new), 10 trimmed or exited.
- AnalystsBULLISH
13 of 23 rate it Buy or better. Every target is above the price.
- EstimatesRISING
Current-quarter EPS estimate −$0.849 → −$0.767 over 90 days. 9 up, 2 down in 30 days.
- Short sellersSTEADY
Short interest +2.8% to 5.75M shares. 7.6 days to cover, ≈8.8% of shares.
- TrendDOWNTREND
11% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Qube Research & Technologies Ltd | TRIM | $8.8M |
| UBS Group AG | ADD | $4.6M |
| RENAISSANCE TECHNOLOGIES LLC | DOUBLED | $4.5M |
| FMR LLC | ADD | $4.0M |
| HRT FINANCIAL LP | DOUBLED | $3.1M |
| Connor, Clark & Lunn Investment Management Ltd. | ADD | $2.4M |
| LOS ANGELES CAPITAL MANAGEMENT LLC | ADD | $987.3K |
| BARCLAYS PLC | ADD | $848.3K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
23 analystsPrice is below the lowest target. Median implies +92%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Nov 3, 2026 | HC Wainwright & Co. MAINTAIN | Buy |
| Aug 10, 2026 | Evercore ISI Group MAINTAIN | Outperform |
| Aug 10, 2026 | Citigroup MAINTAIN | Buy |
| Aug 5, 2026 | Wells Fargo DOWNGRADE | Equal-Weight |
| Aug 5, 2026 | Wedbush MAINTAIN | Neutral |
| Aug 4, 2026 | BTIG REITERATE | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Loomis David K VP, Chief Accounting Officer Nov 9, 2026 | SELL | $1.5K |
Saik Andrew Chief Financial Officer Jun 24, 2026 | SELL | $46.5K |
Bain Linda Director Jun 24, 2026 | AWARD | 15,527 sh |
Bain Linda Director Jun 24, 2026 | AWARD | 22,714 sh |
Norwalk Leslie V Director Jun 24, 2026 | AWARD | 15,527 sh |
Norwalk Leslie V Director Jun 24, 2026 | AWARD | 22,714 sh |
Morrison Briggs Director Jun 24, 2026 | AWARD | 15,527 sh |
Morrison Briggs Director Jun 24, 2026 | AWARD | 22,714 sh |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | -$0.77 | -$0.98–-$0.44 | +17.3% | $11.9M |
| Next Q | -$0.79 | -$0.95–-$0.55 | +12.1% | $12.6M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | -$3.18 | -$4.26–-$2.01 | +1.7% | $47.8M |
Short side
FINRA· Oct 30, 2026SecBot reports
18 filings · 3 press releases · 3 bullish · 5 bearish · 1 mixed · 9 neutral- BEARISH S-3Nov 3, 2026
Arvinas filed a universal shelf registration statement to offer up to $400M in securities…
The shelf filing alongside a 98.8% revenue decline and ongoing cash burn signals that Arvinas will likely tap the ATM facility to extend its runway. Monitor the pace of ATM sales in upcoming filings…
- BEARISH 8-KNov 3, 2026
Arvinas reported Q3 2026 revenue of $0.5M, down 98.8% from $41.9M a year ago, as Pfizer…
The revenue cliff from the Pfizer deal transition is now fully reflected. The stock's valuation will depend entirely on clinical catalysts from ARV-393 (ASH data in December 2026), ARV-027 (1H 2027…
- NEUTRAL PRESS-RELEASENov 3, 2026
Arvinas reported Q3 2026 revenue of $0.5M, down from $41.9M a year ago, as Pfizer collaboration…
Monitor upcoming clinical data presentations for ARV-393 at ASH in December 2026 and ARV-027/ARV-6723 data in 2027, as these are the primary value drivers for this pre-commercial biotech. Cash…
- NEUTRAL 144Sep 4, 2026
Former officer Noah Berkowitz filed Form 144 notices to sell 8,300 shares of Arvinas common stock…
Monitor for actual Form 4 filings confirming the sale. The pattern of consistent insider selling by a former officer, though small in absolute size, may weigh on sentiment. Watch for any…
All ARVN filing & press-release reports (21)
- S-3 reportNov 3, 2026
- 8-K reportNov 3, 2026
- PRESS-RELEASE reportNov 3, 2026
- 144 reportSep 4, 2026
- 8-K reportJun 22, 2026
- 8-K reportJun 2, 2026
- 8-K reportMay 12, 2026
- 8-K reportMay 12, 2026
- PRESS-RELEASE reportMay 12, 2026
- 144 reportMay 8, 2026
- 144 reportMay 8, 2026
- PRESS-RELEASE reportMay 5, 2026
- 8-K reportMay 1, 2026
- PRESS-RELEASE reportMay 1, 2026
- DEFA14A reportApr 29, 2026
- 8-K reportMar 18, 2026
- PRESS-RELEASE reportMar 18, 2026
- PRESS-RELEASE reportMar 11, 2026
- CLUSTER reportFeb 27, 2026
- CLUSTER reportFeb 23, 2026
- CLUSTER reportFeb 23, 2026